Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Stock Information for Evofem Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evofem Biosciences Inc.

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
OTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand Viewing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.